Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases
The differential risk profiles of ICIs-associated-GI adverse events underscore the importance of personalized therapy in oncology.
Authors
- Harikesh Dubey (ORCID: https://orcid.org/0000-0001-6044-5990)
- Syed Arman Rabbani (ORCID: https://orcid.org/0000-0002-8454-8158)
- Mandeep Kumar Arora (ORCID: https://orcid.org/0000-0001-6977-2939)
- Atul Khurana (ORCID: https://orcid.org/0000-0002-6107-7162)
- Sathvik Belagodu Sridhar (ORCID: https://orcid.org/0000-0002-9100-2508)
- Mohamed El‐Tanani (ORCID: https://orcid.org/0000-0002-4735-5445)
- Shrestha Sharma (ORCID: https://orcid.org/0000-0001-8527-3419)
Institutions
- Michigan State University (US)
- Ras al-Khaimah Medical and Health Sciences University (AE)
- Dehradun Institute of Technology University (IN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1080/14740338.2024.2416539
- Citations
- 5
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.75